The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Noninvasive assessment of liver fibrosis
Abstract
A 48-year-old male with a previous longstanding history of intravenous drug abuse is evaluated for a diagnosis of hepatitis C and elevated liver biochemical tests. The aspartate aminotransferase is 59 U/L, and the alanine aminotransferase is 68 U/L. The serum bilirubin is 0.8 mg/dL with an indirect fraction of 0.5 mg/dL, the serum creatinine is 1.1 mg/dL, and the international normalized ratio is 1.0. The serum albumin is 3.9 g/dL. Ultrasound imaging reveals a coarse echotexture without evidence of ascites or intra-abdominal collateral veins. The hepatitis C virus genotype is 1b, and the viral load is 5.6 × 106 IU. You recommend a liver biopsy to determine activity and the stage of fibrosis. The patient asks you whether you can get the same information with blood tests or noninvasive imaging, that is, he wants to know the role of serum markers, ultrasound-based transient elastography (TE), and magnetic resonance elastography (MRE) in such situations. FDA, U.S. Food and Drug Administration; MRE, magnetic resonance elastography; TE, ultrasound-based transient elastography. In the United States alone, an estimated 150,000 persons annually are diagnosed with chronic liver disease with nearly 30,000 (20%) individuals having cirrhosis at initial presentation.1 Disease-related complications of cirrhosis, in turn, are mediated by the development and progression of hepatic fibrosis. Hepatic fibrogenesis is a maladaptative wound-healing process that occurs in response to chronic, injurious stimuli affecting hepatocytes. This results in a stereotypical inflammatory response leading to hepatic stellate cell activation that produces a nonuniform accumulation of extracellular matrix complexes that constitute hepatic fibrosis. The crosslinking of collagen fibrils within extracellular matrix leads to fibrous scar formation and eventual distortion of the hepatic architecture. Notably, the progression of hepatic fibrosis is not a continuous, linear process but rather a discontinuous, stuttering phenomenon that is greatly influenced by factors such as age, sex, race, alcohol exposure, and obesity.2 The gold standard for detecting liver fibrosis remains percutaneous liver biopsy, although this procedure is not without its own inherent limitations. These include (1) a small but significant risk for procedure-related complications such as pain or bleeding, (2) inaccurate staging from sampling error in up to 25% of cases, and (3) inter- and intraobserver variability in biopsy interpretation.3, 4 Because of these reasons and wide availability of serum diagnostic tests, the use of diagnostic liver biopsy in clinical practice is declining.5 From a clinical perspective, the greatest limitation with liver biopsy is sampling variability and its effect on fibrosis staging. Several investigations have documented that sampling error is present in a variety of liver diseases.6, 7 Furthermore, the performance of biopsies involving the right and left liver lobes in the same patient does not reduce sampling error, because substantial discordance in fibrosis stage is observed.7 Although the optimal liver biopsy specimen characteristics (≥20 mm in length with ≥11 portal tracts) have been identified to minimize the effects from sampling error,8 the typical specimen obtained in clinical practice often fails to meet these standards. A variety of serum markers have been developed for identifying patients who are at risk for clinically significant hepatic fibrosis (defined by stages F2-F4). These markers are classified as direct (representing components of extracellular matrix) or indirect (reflecting hepatic inflammation and function). Indirect markers may be used alone or combined with direct markers to form panels. The practical advantages of serum fibrosis markers include their noninvasiveness, potential for widespread availability, and reproducibility when serial examinations are performed using the same laboratory (Table 1).9 Among indirect serum marker panels, the most widely used and validated technique worldwide is called the FibroTest. This proprietary panel contains five variables including total bilirubin, haptoglobin, gamma glutamyl transpeptidase, α2-macroglobulin, and apolipoprotein A. Several independent and combined analyses have demonstrated excellent diagnostic performance for the detection of histological stage F4 fibrosis (i.e., cirrhosis) among patients with chronic hepatitis C. Additional studies in patients with chronic hepatitis B, alcoholic liver disease, nonalcoholic fatty liver disease, as well as studies conducted in the general population, are emerging in support of this method as well. However, serum markers including FibroTest are less accurate in detecting the presence of intermediate stages of fibrosis as compared to the detection of cirrhosis.9, 10 There are specific limitations associated with the use of FibroTest and serum marker panels in general. False positive results can be attributable to (1) decreases in ha
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Magnetic Resonance Elastography by Direct Visualization of Propagating Acoustic Strain Waves
Muthupillai, R., Lomas, D. J., Rossman, P. J., Greenleaf, J. F., Manduca, A., & Ehman, R. L. (1995) · Science · doi:10.1126/science.7569924 · Cited by 2,116 · cited 1×
“Region-of-interest analysis throughout four cross-sectional slices of liver (avoiding vascular structures) is then performed to calculate mean liver stiffness.(15) Elasticity quantification by MRE is based on the formula representing shear modulus, which is equivalent to one-third of the Young’s modulus used with TE.”
Cited by
En Li Cho, E., Ang, C. Z., Quek, J., Fu, C. E., Lim, L. K. E., Heng, Z. E. Q., Tan, D. J. H., Lim, W. H., Yong, J. N., Zeng, R., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-330110 · Cited by 380
Lichtinghagen, R., Pietsch, D., Bantel, H., Manns, M. P., Brand, K., & Bahr, M. J. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.03.016 · Cited by 370
Rinella, M. E., Dufour, J.-F., Anstee, Q. M., Goodman, Z., Younossi, Z., Harrison, S. A., Loomba, R., Sanyal, A. J., Bonacci, M., Trylesinski, A., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.029 · Cited by 164
Macrophage-Derived Cathepsin S Remodels the Extracellular Matrix to Promote Liver Fibrogenesis
Zuo, T., Xie, Q., Liu, J., Yang, J., Shi, J., Kong, D., Wang, Y., Zhang, Z., Gao, H., Zeng, D.-B., et al. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.05.039 · Cited by 70
Metadata
- Authors
- Nguyen, D., & Talwalkar, J. A.
- Venue
- Hepatology
- Published
- 2011-06
- Volume
- 53
- Issue
- 6
- Pages
- 2107-2110
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2020110969
- Cited by
- 172
- References
- 1
- FWCI
- 8.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Noninvasive assessment of liver fibrosis. https://app.cochat.ai/papers/10.1002/hep.24401
- The paper
- Nguyen, D., & Talwalkar, J. A. (2011). Noninvasive assessment of liver fibrosis. Hepatology. https://doi.org/10.1002/hep.24401
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.